How do you counsel patients about the potential malignancy risk associated with traditional DMARDs?
Answer from: at Academic Institution
I discuss with them the slight increase of non-melanoma skin cancer in studies of methotrexate. Otherwise, there is not convincing data of associations between csDMARDs and cancer development.
Comments
at Arthritis Associates I also include the increased risk of malignancy se...
I also include the increased risk of malignancy se...